Asset
Milsaperidone
Vanda Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04969211 | phase1 | completed | 2021-06-30 | 2021-10-13 | Vanda Pharmaceuticals | Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers |
| NCT06830044 | phase3 | recruiting | 2025-03-03 | 2028-03-01 | Vanda Pharmaceuticals | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder |
| NCT06803290 | phase1 | completed | 2022-06-21 | 2022-12-27 | Vanda Pharmaceuticals | Food Effect Study of VHX-896 in Healthy Volunteers |
| NCT06494397 | phase1 | completed | 2024-07-11 | 2024-10-24 | Vanda Pharmaceuticals | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220358 | NDA | VANDA PHARMACEUTICALS INC |
Marketed products (7)
- BYSANTI
- BYSANTI
- BYSANTI
- BYSANTI
- BYSANTI
- BYSANTI
- BYSANTI